Correlation study of metabolic syndrome with clinicopathological features and prognosis in patients with pancreatic cancer

XIE Chunxiao; LU Jiexia; CHEN Fengping; WEI Dafu; SHI Qiuyue; QIN Shanyu

doi:10.16190/j.cnki.45-1211/r.2024.01.011

Journal of Guangxi Medical University > 2024 > 41(1): 78-84. > DOI: 10.16190/j.cnki.45-1211/r.2024.01.011

XIE Chunxiao, LU Jiexia, CHEN Fengping, WEI Dafu, SHI Qiuyue, QIN Shanyu. Correlation study of metabolic syndrome with clinicopathological features and prognosis in patients with pancreatic cancer[J]. Journal of Guangxi Medical University, 2024, 41(1): 78-84. DOI: 10.16190/j.cnki.45-1211/r.2024.01.011

Citation:

PDF (1273 KB)

Correlation study of metabolic syndrome with clinicopathological features and prognosis in patients with pancreatic cancer

Department of Gastroenterology, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China

More Information

Received Date: December 17, 2023
Available Online: March 26, 2024

Graphical Abstract

Abstract

Abstracts

Objective: To investigate the correlation of metabolic syndrome (MS) and its components with the clinicopathological features in patients with pancreatic cancer and their prognostic impact, so as to provide a theoretical reference for the comprehensive prevention and treatment of pancreatic cancer.Methods: A retrospective analysis was conducted on the case data of 184 patients with pancreatic cancer who received treatment at the First Affiliated Hospital of Guangxi Medical University from January 2017 to December 2021.Based on the diagnostic criteria for metabolic syndrome, the 144 cases were divided into non-MS group (n=104) and MS group (n=40).Cox regression model was used to analyze prognostic factors in 49 patients without anticancer treatment, while Kaplan-Meier method was employed to examine the relationship between MS and its components with prognosis.Results: Compared with the non-MS group, the MS group exhibited advanced TNM stage and a higher incidence rate of distant metastasis (P< 0.05).Low level of high-density lipoprotein cholesterol (HDL-C) and hyperglycemia were independent risk factors for TNM staging of pancreatic cancer(P< 0.05).The median survival time for the 49 patients without anticancer therapy was determined as 2.5 months.Survival analysis showed that advanced TNM stage and hyperglycemia were independent risk factors for survival time (P< 0.05), and the median survival time of stage Ⅳpatients was 2.2 months.Hyperglycemia was an independent risk factor for the prognosis of stage Ⅳpatients, and overweight was a protective factor(both P< 0.05).There was no statistical significance in survival time between MS patients and non-MS patients(P> 0.05), and there was no statistical significance in median survival time between patients with or without hypertension, high triglyceride (TG) and low HDL-C(all P> 0.05).Conclusion: MS is related to clinical stage and incidence of distant metastasis of pancreatic cancer patients, but it has not been proved to be an influencing factor for the survival of patients.Hyperglycemia and overweight are risk factors and protective factors for the prognosis of patients.
- metabolic syndrome;
- pancreatic cancer;
- tumor stage;
- prognosis

FullText(HTML)

References (25)

References

[1]	XIA C, DONG X, LI H, et al.Cancer statistics in China and United States, 2022:profiles, trends, and determinants[J].Chinese medical journal, 2022, 135(5):584-590.
[2]	SUNG H, FERLAY J, SIEGEL R L, et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J].CA:a cancer journal for clinicians, 2021, 71(3):209-249.
[3]	ISHII Y, SERIKAWA M, TSUBOI T, et al.Role of Endoscopic ultrasonography and endoscopic retrograde cholangiopancreatography in the diagnosis of pancreatic cancer[J].Diagnostics(Basel, Switzerland), 2021, 11(2).
[4]	AMBROSELLI D, MASCIULLI F, ROMANO E, et al.New advances in metabolic syndrome, from prevention to treatment:the role of diet and food [J].Nutrients, 2023, 15(3):640.
[5]	KARRA P, WINN M, PAULECK S, et al.Metabolic dysfunction and obesity-related cancer:Beyond obesity and metabolic syndrome[J].Obesity, 2022, 30(7):1323-1334.
[6]	诸骏仁, 高润霖, 赵水平, 等.中国成人血脂异常防治指南(2016 年修订版)[J].中国循环杂志, 2016, 31 (10):937-953.
[7]	中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志, 2007, 35(5):390-419.
[8]	ZHONG L, LIU J, LIU S, et al.Correlation between pancreatic cancer and metabolic syndrome:A systematic review and meta-analysis [J].Frontiers in endocrinology, 2023, 14:1116582.
[9]	XIA B, HE Q, PAN Y, et al.Metabolic syndrome and risk of pancreatic cancer:A population-based prospective cohort study[J].International journal of cancer, 2020, 147(12):3384-3393.
[10]	WANG D S, WANG Z Q, ZHANG L, et al.Are risk factors associated with outcomes in pancreatic cancer? [J].PLos one, 2012, 7(7):e41984.
[11]	KHALAF N, KRAMER J, LIU Y, et al.Diabetes status and pancreatic cancer survival in the nationwide veterans affairs healthcare system [J].Digestive diseases and sciences, 2023, 68(9):3634-3643.
[12]	HE X Y, LI J F, YAO W Y, et al.Resolution of new-onset diabetes after radical pancreatic resection predicts longterm survival in patients with pancreatic ductal cell adenocarcinoma [J].Annals of surgical oncology, 2013, 20(12):3809-3816.
[13]	BEN Q, XU M, JIANG Y, et al.Clinical profiles and longterm outcomes of patients with pancreatic ductal adenocarcinoma and diabetes mellitus [J].Diabetes/metabolism research and reviews, 2012, 28(2):169-176.
[14]	LEE D H, GIOVANNUCCI E L.The obesity paradox in cancer:epidemiologic insights and perspectives [J].Current nutrition reports, 2019, 8(3):175-181.
[15]	LAUBY-SECRETAN B, SCOCCIANTI C, LOOMIS D, et al.Body fatness and cancer-viewpoint of the iarc working group [J].The New England journal of medicine, 2016, 375(8):794-798.
[16]	BAO B, WANG Z, LI Y, et al.The complexities of obesity and diabetes with the development and progression of pancreatic cancer [J].Biochimica et biophysica acta, 2011, 1815(2):135-146.
[17]	RUZE R, SONG J, YIN X, et al.Mechanisms of obesityand diabetes mellitus-related pancreatic carcinogenesis:a comprehensive and systematic review[J].Signal transduction and targeted therapy, 2023, 8(1):139.
[18]	WU B, SHEN W, WANG X, et al.Plasma lipid levels are associated with the CD8+T-cell infiltration and prognosis of patients with pancreatic cancer [J].Cancer medicine, 2023, 12(13):14138-14148.
[19]	KABAT G C, KIM M Y, CHLEBOWSKI R T, et al.Serum lipids and risk of obesity-related cancers in postmenopausal women [J].Cancer causes & control, 2018, 29(1):13-24.
[20]	杨健, 樊知遥, 李永政, 等.胰腺癌患者的血脂谱特点及其与临床和病理学特征的相关性分析[J].中华外科杂志, 2022, 60(7):680-687.
[21]	OBERLE R, KÜHRER K, ÖSTERREICHER T, et al.The HDL particle composition determines its antitumor activity in pancreatic cancer [J].Life science alliance, 2022, 5(9):e202101317.
[22]	邓青, 程蔚蔚, 陈岚.高密度脂蛋白胆固醇、铁蛋白、整合素α3 与Ⅳ期非小细胞肺癌病理特征及患者生存预后的相关性[J].实用癌症杂志, 2022, 37(10):1591-1595.
[23]	范大光, 梁焕芳, 马剑方.血清脂蛋白与胃癌淋巴结转移及肿瘤分期的关系[J].肿瘤研究与临床, 2011, 23(7):447-449.
[24]	韩金星, 韩荣.PA、LDH 和HDL-C 表达水平与晚期结直肠癌近期疗效和病情进展的相关性[J].中国肛肠病杂志, 2022, 42(4):16-18.
[25]	LIAO F, HE W, JIANG C, et al.A high LDL-C to HDL-C ratio predicts poor prognosis for initially metastatic colorectal cancer patients with elevations in LDL-C [J].Oncotargets and therapy, 2015, 8:3135-3142.

Cited By

Get Citation

PDF

XML

Article views (70) PDF downloads (9)

Turn off MathJax

Article Contents

Abstracts

References

Correlation study of metabolic syndrome with clinicopathological features and prognosis in patients with pancreatic cancer

Abstracts

References

Catalog

Export File

Citation

Format

Content